We found that patients with oligometastatic TNBC tend to have worse OS and PFS compared to patients with oligometastatic HR+/HER2‐ breast cancer; however, only five patients had TNBC, so the effects of SABR for OM in this population are still unclear. Here, ERBB2 is linked to breast cancer.